Taken together, our findings suggest that VEGF‐A inhibition may directly target cellular pathways involved in lipid metabolism in psoriasis non‐lesional skin, which potentially offers a treatment strategy to improve dyslipidaemia in psoriasis. The gene discussed is VEGFA; the disease is psoriasis.